Corpus Curare Spiritumque
A promising antimicrobial agent known to kill, kill bacteria and viruses can also stimulate the innate immune system, according to researchers at National Jewish Health. In a document, the June 4th line in the Journal of Investigative Dermatology, Michael Howell, PhD, Assistant Professor of Pediatrics, and colleagues have shown that the synthesis connection CSA-13 can kill vaccinia virus in cell cultures and in the mouse. They also showed that CSA-13-stimulated cells for their own antimicrobial proteins. “This connection shows wide efficiency,” said Dr Howell.
“While our experiments have been designed for its ability to attack on the vaccinia virus, stimulating the immune system has an amazing ability of observation.”
CSA-13 is one of a class of compounds known as ceragenins that have been developed to Brigham Young University Professor Paul Savage antimicrobials to imitate naturally occurring proteins in the body. The ceragenins smaller than proteins and antimicrobial agents are not as vulnerable to degradation in the body. They have shown that effective fight against a large number of species of bacteria.
Dr. Howell and his colleagues wanted to know whether CSA-13 could fight vaccinia virus infection. Vaccinia virus is closely related to the body, which means that the smallpox and the smallpox vaccine. But millions of people in the United States had eczema are susceptible to serious and potentially fatal complication of vaccination, also known as eczema Vaccinatum, which occurs when the vaccinia virus skin. Dr. Howell is part of a team led by Professor of Allergy and Clinical Immunology Donald Leung, MD, PhD, is the search for protection against this complication, so that eczema patients, vaccination case of biological attack with the virus.
CSA-13 shows efficacy against Vaccinia in three tests. At the CSA and 13 vaccinia virus incubated directly, CSA 13, which killed more than 96% of the virus at a concentration of 25 micromolar. In the CSA-13 was added to Vaccinia infected cells, but also reduce vaccinia virus genes and allows more of the infected cells to survive. Finally, researchers have affected the immune systems of mice infected with vaccinia virus, and CSA-13 on their skin. CSA-13 reduced the number of injuries, the vaccinia virus.
“These experiments have shown final for the first time, CSA-13 can not fight effectively against vaccinia virus infection,” said senior author Dr. Leung.
In their experiments, researchers found that, in addition to directly kill the virus, CSA-13-stimulated cells for their own antimicrobial proteins, LL-37 and HBD-3. Dr. Howell and his colleagues have already shown that these proteins Expozitie same antimicrobial antiviral activity against vaccinia virus.
“We knew our plate tests, as CSA-13 was directly kill the virus,” said Dr Howell. “But these experiments show that also stimulates the cells to their own antimicrobial protein, to fight against their disease. Our next step is to find out how CSA-13-stimulated cells in innate immune defense.”
A promising antimicrobial agent known to kill, kill bacteria and viruses can also stimulate the innate immune system, according to researchers at National Jewish Health. In a document, the June 4th line in the Journal of Investigative Dermatology, Michael Howell, PhD, Assistant Professor of Pediatrics, and colleagues have shown that the synthesis connection CSA-13 can kill vaccinia virus in cell cultures and in the mouse. They also showed that CSA-13-stimulated cells for their own antimicrobial proteins. “This connection shows wide efficiency,” said Dr Howell.
“While our experiments have been designed for its ability to attack on the vaccinia virus, stimulating the immune system has an amazing ability of observation.”
CSA-13 is one of a class of compounds known as ceragenins that have been developed to Brigham Young University Professor Paul Savage antimicrobials to imitate naturally occurring proteins in the body. The ceragenins smaller than proteins and antimicrobial agents are not as vulnerable to degradation in the body. They have shown that effective fight against a large number of species of bacteria.
Dr. Howell and his colleagues wanted to know whether CSA-13 could fight vaccinia virus infection. Vaccinia virus is closely related to the body, which means that the smallpox and the smallpox vaccine. But millions of people in the United States had eczema are susceptible to serious and potentially fatal complication of vaccination, also known as eczema Vaccinatum, which occurs when the vaccinia virus skin. Dr. Howell is part of a team led by Professor of Allergy and Clinical Immunology Donald Leung, MD, PhD, is the search for protection against this complication, so that eczema patients, vaccination case of biological attack with the virus.
CSA-13 shows efficacy against Vaccinia in three tests. At the CSA and 13 vaccinia virus incubated directly, CSA 13, which killed more than 96% of the virus at a concentration of 25 micromolar. In the CSA-13 was added to Vaccinia infected cells, but also reduce vaccinia virus genes and allows more of the infected cells to survive. Finally, researchers have affected the immune systems of mice infected with vaccinia virus, and CSA-13 on their skin. CSA-13 reduced the number of injuries, the vaccinia virus.
“These experiments have shown final for the first time, CSA-13 can not fight effectively against vaccinia virus infection,” said senior author Dr. Leung.
In their experiments, researchers found that, in addition to directly kill the virus, CSA-13-stimulated cells for their own antimicrobial proteins, LL-37 and HBD-3. Dr. Howell and his colleagues have already shown that these proteins Expozitie same antimicrobial antiviral activity against vaccinia virus.
“We knew our plate tests, as CSA-13 was directly kill the virus,” said Dr Howell. “But these experiments show that also stimulates the cells to their own antimicrobial protein, to fight against their disease. Our next step is to find out how CSA-13-stimulated cells in innate immune defense.”
